Candel Therapeutics

CADL

Market cap $266M

Overview Fund Activity

4.84 USD

-0.01

0.21%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

4.84

0.00

0%

1 day

-0.21%

5 days

-0.21%

1 month

-18.79%

3 months

-2.02%

6 months

-45.19%

Year to date

-46.16%

1 year

-31.15%

5 years

-30.86%

10 years

-30.86%

About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Employees: 38

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

276% more call options, than puts

Call options by funds: $4.56M | Put options by funds: $1.21M

186% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 14

1.11% more ownership

Funds ownership: 44.86% [Q1] → 45.96% (+1.11%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

3% less capital invested

Capital invested by funds: $120M [Q1] → $117M (-$3.19M) [Q2]

5% less funds holding

Funds holding: 82 [Q1] → 78 (-4) [Q2]

20% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 20

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

45% upside

Avg. target

$15

210% upside

High target

$23

375% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

B of A Securities Alec Stranahan	$7	Neutral Downgraded	3 Sep 2025
HC Wainwright & Co. Andrew Fein	$23	Buy Assumed	30 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CADL published over the past 30 days

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place from September 27 to October 1, 2025, in San Francisco, CA. The oral presentation will feature data from the Company's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer.

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics: Potentially The Next Exciting Oncology Story

I rate Candel Therapeutics a Buy, seeing significant upside potential versus current valuation, driven by CAN-2409's blockbuster prospects in immunotherapy oncology. CAN-2409's strong phase III prostate cancer results, RMAT designation, and 60% approval odds support my bullish thesis; lung and pancreatic cancer indications add further optionality. My sales projections for CAN-2409 suggest multi-billion dollar annual revenues by 2030, with cash flows ramping up as commercial launches begin.

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is financially solid after a $92 million capital raise, ensuring a cash runway through 2027 and supporting late-stage clinical and regulatory milestones. Candel's differentiated oncolytic viral platform and FDA Fast Track designations position it as a leader in a rapidly maturing immuno-oncology niche.

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Proactive Investors

Candel Therapeutics adds immunotherapy expert to Research Advisory Board

Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on viral immunotherapies, announced the appointment of Dr Carl June to its Research Advisory Board. Dr June is an internationally recognized leader in cancer immunotherapy and played a key role in developing the first FDA-approved CAR-T cell therapy.

Candel Therapeutics adds immunotherapy expert to Research Advisory Board

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H.

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings.

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Proactive Investors

Candel Therapeutics secures RMAT for prostate cancer – ICYMI

Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs. CEP Dr Paul Peter Tak said Candel has had “another very successful quarter”, highlighting that its lead program CAN-2409 achieved its primary endpoint in early localized, newly diagnosed prostate cancer.

Candel Therapeutics secures RMAT for prostate cancer – ICYMI

Proactive Investors

Candel Therapeutics advances toward prostate cancer therapy filing after trial success

Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status. The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help support launch readiness activities.

Candel Therapeutics advances toward prostate cancer therapy filing after trial success

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the second quarter ended June 30, 2025, and provided a corporate update.

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA.

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

See News Rankings

Charts implemented using Lightweight Charts™